Similar articles

• Incorporating monoclonal antibodies into the therapy of multiple myeloma.

  Bladé J, de Larrea CF, Rosiñol L. Bladé J, et al. J Clin Oncol. 2012 Jun 1;30(16):1904-6. doi: 10.1200/JCO.2011.40.4178. Epub 2012 Jan 30. J Clin Oncol. 2012. PMID: 22291081 No abstract available.
• Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy.

  Kuroda J, Mizutani S, Shimura Y, Maegawa S, Nagoshi H, Chinen Y, Tatekawa S, Tsukamoto T, Mizuno Y, Yamamoto-Sugitani M, Kobayashi T, Matsumoto Y, Horiike S, Taniwaki M. Kuroda J, et al. Ann Hematol. 2015 Apr;94(4):687-9. doi: 10.1007/s00277-014-2214-x. Epub 2014 Sep 12. Ann Hematol. 2015. PMID: 25209844 No abstract available.
• [Analysis of Bortezomib-containing combinations in newly-diagnosed multiple myeloma patients: a comparative study].

  Xu L, Qiu H, Hu X, Lyu S, Song X, Chen L, Zhang W, Gao L, Xu X, Wang J, Yang J. Xu L, et al. Zhonghua Xue Ye Xue Za Zhi. 2014 May;35(5):448-50. doi: 10.3760/cma.j.issn.0253-2727.2014.05.015. Zhonghua Xue Ye Xue Za Zhi. 2014. PMID: 24857218 Chinese. No abstract available.
• Position statement on the use of bortezomib in multiple myeloma.

  Morgan GJ, Davies FE, Cavenagh JD, Jackson GH; United Kingdom Myeloma Forum (UKMF); Haematology Oncology Task Force of the British Committee for Standards in Haematology. Morgan GJ, et al. Int J Lab Hematol. 2008 Feb;30(1):1-10. doi: 10.1111/j.1751-553X.2007.01020.x. Int J Lab Hematol. 2008. PMID: 18190461 Review.
• Bortezomib in the front-line treatment of multiple myeloma.

  Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC. Richardson PG, et al. Expert Rev Anticancer Ther. 2008 Jul;8(7):1053-72. doi: 10.1586/14737140.8.7.1053. Expert Rev Anticancer Ther. 2008. PMID: 18588451 Review.